The two shots didn't seem to give her a robust immune response due to a lab test; She's kind of having a headache today; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. Relevant medical history included: "Immunocompromised" (unspecified if ongoing). The patient took concomitant medications. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), for Covid-19 immunization, reaction(s): "Decreased immune responsiveness". The following information was reported: DECREASED IMMUNE RESPONSIVENESS (non-serious), outcome "unknown", described as "The two shots didn't seem to give her a robust immune response due to a lab test"; HEADACHE (non-serious) with onset 12May2021, outcome "unknown", described as "She's kind of having a headache today". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: The patient received both doses of the Pfizer-BioNtech Covid-19 vaccine, she took immunosuppressive medications (injection). She's interested in knowing if Pfizer was conducting a clinical trial in patients who were immunocompromised taking a third dose of the Pfizer-BioNtech Covid-19 vaccine. The patient stated that the two shots didn't seem to give her a robust immune response due to a lab test, she asked someone who worked at the lab company about the antibodies range and they were kind of flying blind but usually see results between 15-16 thousand and hers was low compared to that, for the first dose the result were almost undetectable. She also said that immunocompromised people had an inadequate response to the double vaccination and low antibodies, that's why she's wondering if Pfizer was investigating this. The patient said that she's kind of having a headache today and during the call she also mentioned that she's having an expensive dental work coming up. The patient refused to be transferred to Safety. During the call she provided her contact information however she didn't want it to be transferred to another department, she declined to provide any other information. AE E-transmitting. Referred caller to her HCP. The patient would like to know if there were studies that track the antibodies level in people who takes immunosuppressive therapy that receive the Pfizer-BioNtech Covid-19 vaccine. The patient said that she's a guinea pig and a defective clinical trial. She said that it's bad that Pfizer was not following immunosuppressed patients who received the Pfizer- BioNTech Covid-19 vaccine more closely. She said that it's a problem that nobody had information on Ab standards and that there's no guidance for doctors on the ranges. She also said that because of this she was not out of lockdown and she wanted to have life. She believed that eventually if the booster was safe then somebody might have the guts to say that it could be considered for immunocompromised patients, but she didn't think that Pfizer was going to do that. The patient wanted to let Pfizer know that there should be a trial conducted in immunocompromised people receiving the Covid vaccine. She understood that initially the vaccine was tested on healthy people who could better withstand side-effects, but maybe Pfizer wanted to keep the numbers looking god in terms of 95% efficacy but she thought Pfizer should start having the guts that once tested the third dose in healthy people this should be done in immunocompromised people as a public service, she thought that it's something related to marketing (market decline) and that she could be wrong but this trial would be a public service.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.